BRINGING BIOSIMILAR SCIENCE
TO CERTAIN RETINAL VASCULAR
DISORDERS1

Introducing BYOOVIZ: A Biosimilar* Referencing Lucentis1

  • FDA-approved for the treatment of nAMD, macular edema following RVO, and mCNV1
  • Similar efficacy and comparable safety and immunogenicity2,3
  • No clinically meaningful differences from Lucentis based on the totality of evidence2,3
  • 0.5 mg (0.05 mL of 10 mg/mL) dosing administered by intravitreal injection once a month1
  • *
  • Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.

BYOOVIZ Met FDA Requirements for Biosimilar Approval in All Studies Conducted2-5

BYOOVIZ was evaluated for biosimilarity in an nAMD clinical study and was granted approval for macular edema following RVO and mCNV through a process called "extrapolation." Extrapolation of clinical data to other indications of the reference product is considered in light of the totality of evidence and must be scientifically justified.1-6

BYOOVIZ is FDA-approved for the treatment of nAMD, macular edema following RVO, and mCNV1

FDA=US Food and Drug Administration; mCNV=myopic choroidal neovascularization; nAMD=neovascular age-related macular degeneration; RVO=retinal vein occlusion.

INDICATIONS

BYOOVIZ™ (ranibizumab-nuna), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Myopic Choroidal Neovascularization (mCNV)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • BYOOVIZ is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in BYOOVIZ
  • Hypersensitivity reactions may manifest as severe intraocular inflammation

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with ranibizumab products, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering BYOOVIZ. In addition, patients should be monitored following the injection to permit early treatment should an infection occur

Increases in Intraocular Pressure

  • Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with ranibizumab products. Monitor intraocular pressure prior to and following intravitreal injection with BYOOVIZ and manage appropriately

Thromboembolic Events

  • Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. Arterial thromboembolic events are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause)
    • Neovascular (Wet) Age-Related Macular Degeneration
    • The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of ranibizumab-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the 0.5 mg arms during the first and second year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3
      In a pooled analysis of 2-year controlled studies [AMD-1, AMD-2, and a study of ranibizumab used adjunctively with verteporfin photodynamic therapy (PDT)], the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg of ranibizumab compared to 1.1% (5 of 435) in patients in the control arms [odds ratio 2.2 (95% confidence interval (0.8-7.1)]
    • Macular Edema Following Retinal Vein Occlusion
    • The ATE rate in the two controlled RVO studies during the first 6 months was 0.8% in both the ranibizumab and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of ranibizumab-treated patients compared to 0.4% (1 of 260) in the control arms

ADVERSE REACTIONS

  • Serious adverse reactions related to the injection procedure have occurred in < 0.1% of intravitreal injections, including endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract
  • The most common adverse reactions (reported more frequently in ranibizumab-treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure
  • As with all therapeutic proteins, there is potential for immunogenicity. The clinical significance of immunoreactivity to ranibizumab products is unclear at this time

Please see full Prescribing Information.

References

  1. BYOOVIZ Prescribing Information, Cambridge, MA: Biogen, 2022.
  2. Woo SJ, Veith M, Hamouz J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2021;139(1):68-76. doi:10.1001/jamaophthalmol.2020. 5053
  3. Bressler NM, Veith M, Hamouz J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2021;bjophthalmol-2021- 319637. doi:10.1136/bjophthalmol-2021-319637
  4. US Department of Health and Human Services. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Guidance for Industry. Washington, DC: US Dept of Health and Human Services; April 2015.
  5. US Food and Drug Administration. Center for Drug Evaluation and Research. Application Number: 761202Orig1s000 Byooviz Multi-Discipline Review. https:// www.accessdata.fda.gov/drugsatfda_docs/nda/2021/ 761202Orig1s000MultidisciplineR.pdf. September 17, 2020. Accessed September 25, 2022.
  6. Wolff-Holz E, Garcia Burgos J, Giuliani R, et al. Preparing for the incoming wave of biosimilars in oncology. ESMO Open. 2018;3(6):e000420. doi:10.1136/esmoopen-2018-000420
Terms and Conditions Privacy Policy Contact Us Cookie Policy Notice to CA Residents

For US Healthcare Professionals Only
Lucentis is a registered trademark of Genentech, Inc.
All other trademarks are the property of their respective owners.
© 2024 Biogen. All rights reserved. 07/24 BYO-US-0182v4